Alzamend Neuro is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s.
View Top Employees from Alzamend Neuro| Website | http://www.alzamend.com |
| Revenue | $11 million |
| Employees | 9 (2 on RocketReach) |
| Founded | 2016 |
| Address | 3480 Peachtree Rd NE 2nd FL, suite 121, Atlanta, Georgia 30303, US |
| Phone | (844) 722-6333 |
| Industry | Biotechnology Research, Pharmaceuticals, Healthcare |
| SIC | SIC Code 873 Companies, SIC Code 87 Companies |
| NAICS | NAICS Code 5417 Companies, NAICS Code 541714 Companies, NAICS Code 54 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 3254 Companies |
Looking for a particular Alzamend Neuro employee's phone or email?
Alzamend Neuro Questions
The Alzamend Neuro annual revenue was $11 million in 2024.
Stephan Jackman is the Chief Executive Officer and Director of Alzamend Neuro.
2 people are employed at Alzamend Neuro.
Alzamend Neuro is based in Atlanta, Georgia.
The NAICS codes for Alzamend Neuro are [5417, 541714, 54, 325, 32, 541, 54171, 3254].
The SIC codes for Alzamend Neuro are [873, 87].
Top Alzamend Neuro Employees
-
45+
-
1
Related Companies
